CLEC12A/MICL/CLL-1 hFc Chimera, Human
CLEC12A/MICL/CLL-1 HFc Chimera, Human

Immobilized CLEC12A/MICL/CLL-1 hFc Chimera, Human at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-CLEC12A Antibody, hFc Tag with the EC50 of 19.0 ng/ml determined by ELISA.

CLEC12A/MICL/CLL-1 HFc Chimera, Human

The purity of CLEC12A/MICL/CLL-1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

CLEC12A/MICL/CLL-1 HFc Chimera, Human

CLEC12A/MICL/CLL-1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CLEC12A/MICL/CLL-1 hFc Chimera, Human

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.
Z03958
¥78,348.00

Ask us a question
Product Introduction
Species Human
Protein Construction
hFc CLEC12A/MICL/CLL-1 (His65-Ala265)
Accession # Q5QGZ9-2
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Immobilized CLEC12A/MICL/CLL-1 hFc Chimera, Human (Cat.No.: Z03958) at 0.5 μg/ml (100μl/Well) on the plate can bind Biotinylated Anti-CLEC12A Antibody, hFc Tag
Expression System HEK293
Theoretical Molecular Weight 50.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 68-73 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • CLEC12A/MICL/CLL-1 HFc Chimera, Human
    • CLEC12A/MICL/CLL-1 HFc Chimera, Human

    Immobilized CLEC12A/MICL/CLL-1 hFc Chimera, Human at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-CLEC12A Antibody, hFc Tag with the EC50 of 19.0 ng/ml determined by ELISA.

  • CLEC12A/MICL/CLL-1 HFc Chimera, Human
    • CLEC12A/MICL/CLL-1 HFc Chimera, Human

    The purity of CLEC12A/MICL/CLL-1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • CLEC12A/MICL/CLL-1 HFc Chimera, Human
    • CLEC12A/MICL/CLL-1 HFc Chimera, Human

    CLEC12A/MICL/CLL-1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background CLEC12A, also known as CLL-1 is inhibitory C-type lectin-like receptor with ITIM motif. It can associate with signaling phosphatases SHP-1 and SHP-2. CLEC12A is a potential target due to its high expression in acute myeloid leukemia (AML) cells. And there are various therapeutic approaches using CLEC12A as a target for AML, such as CD3/ CLEC12A antibody. It can recruit unstimulated primary T cells against cancer cells with CLL-1 on the surface.
Synonyms MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.